1
Christoph Arth, Andreas Kollmeyer Seeger, Stephan Rimpler, Hans Michael Wolff: Transdermal therapeutic system containing pergolide. Schwarz Pharma, Marshall Gerstein & Borun, October 8, 2002: US06461636 (50 worldwide citation)

The invention relates to a transdermal therapeutic system (TTS) for the transcutaneous administration of pergolide over several days and to a method for its manufacture without using solvents. The TTS contains a matrix mass, containing pergolide and taking the form of a layer, which contains a (meth ...


2
Christoph Arth, Claus Meese, Dietrich Wilhelm Schacht, Hans Michael Wolff: Transdermal therapeutic system TTS containing tolterodine. Schwarz Pharma, Peter F Corless, Christine C O&apos Day, Edwards & Angell, August 31, 2004: US06783769 (31 worldwide citation)

The invention relates to a transdermal therapeutic system (TTS) for transcutaneously administering tolterodine over a period of several days and to a method for producing the same. The TTS contains a self-adhesive layer-shaped matrix composition which contains a (meth)acrylate copolymer comprising a ...


3
Hans Michael Wolff, Christoph Arth: Therapeutical system for transdermal delivery of levonorgestrel. Schwarz Pharma, Marshall Gerstein & Borun, April 29, 2003: US06555131 (17 worldwide citation)

A stable therapeutical transdermal system for the transcutaneous delivery of levonorgestrel, alone or together with other sex steroid hormones, over a long time period is disclosed. A method of producing the transdermal system that avoids the use of solvents and avoids degradation of the steroid hor ...


4
Hans Michael Wolff, Christoph Arth: Schwarz Pharma, Marshall Gerstein & Borun, May 13, 2003: US06562367 (14 worldwide citation)

A transdermal therapeutic system for transcutaneous administration of sexual steroid hormones over long time periods, and a solvent-free method for the production thereof, is disclosed. The steroid hormones are subjected to as little thermal exposure as possible, thereby avoiding decomposition of th ...


5
Christoph Arth, Andreas Kollmeyer Seeger, Stephan Rimpler, Hans Michael Wolff: Transdermal therapeutic system (TTS) containing oxybutynin. Schwarz Pharma, Marshall Gerstein & Borun, April 29, 2003: US06555129 (3 worldwide citation)

A transdermal therapeutic system (TTS) for transcutaneous administration of oxybutynin over a period of several days, in addition to a method for the production of the TTS without the use of solvents, are disclosed. The TTS contains a matrix mass containing oxybutynin in the form of a self-adhesive ...


6
Christoph Arth, Michael Komenda, Fatima Bicane, Hans Jurgen Mika: Pharmaceutical compositions comprising fesoterodine. UCB Pharma, Kenyon & Kenyon, October 5, 2010: US07807715 (1 worldwide citation)

The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and comb ...


7
Hans Michael Wolff, Christoph Arth, Luc Quere, Walter Müller: Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine. UCB Pharma, LTS Lohmann Therapie Systeme, Harness Dickey and Pierce, November 20, 2018: US10130589

The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9: ...


8
Hans Jürgen Mika, Christoph Arth, Michael Komenda, Fatima Bicane, Kerstin Paulus, Meike Irngartinger, Hans Lindner: Pharmaceutical compositions comprising fesoterodine. UCB Pharma, Kenyon & Kenyon, August 6, 2013: US08501723

The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and comb ...


9
Hans Jürgen Mika, Christoph Arth, Michael Komenda, Fatima Bicane: Pharmaceutical compositions comprising Fesoterodine. UCB PHARMA, Kenyon & Kenyon, June 14, 2016: US09364541

The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and comb ...


10
Hans Jürgen Mika, Christoph Arth, Michael Komenda, Fatima Bicane: Pharmaceutical compositions comprising fesoterodine. UCB Pharma, Kenyon & Kenyon, January 3, 2012: US08088398

The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and comb ...